$CVM CEL-SCI Reports Fiscal First Quarter 2026 Results
Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study
Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization
VIENNA, Va.--(BUSINESS WIRE)--
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.
“CEL-SCI is focused on two major value-driving milestones in the near term—starting enrollment in our U.S. FDA confirmatory Registration trial of Multikine in head and neck cancer and advancing Multikine globally in markets including Saudi Arabia. We plan to commence enrollment this summer in our confirmatory study of Multikine in head and neck cancer. Data from this study will be submitted as part of registration applications to allow commercialization and sale of Multikine in the U.S. and other key global markets. Prior studies have shown that pre-surgical tumor responses, such as tumor size reduction and downgrading of the disease by a physician, following Multikine treatment predict substantial survival benefit for the patients. We believe that these pre-surgical tumor responses after the three-week treatment with Multikine, before any other treatment has been administered, could be the basis of an accelerated marketing application for Multikine,” stated CEL-SCI CEO, Geert Kersten. “Concurrently, we have been active in Saudi Arabia, pursuing the potential for Multikine to be available to patients with head and neck cancer following the filing for Breakthrough Medicine Designation there in the second half of 2025.”
https://www.stocktitan.net/news/CVM/cel-sci-r...dwmth.html
Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study
Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization
VIENNA, Va.--(BUSINESS WIRE)--
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.
“CEL-SCI is focused on two major value-driving milestones in the near term—starting enrollment in our U.S. FDA confirmatory Registration trial of Multikine in head and neck cancer and advancing Multikine globally in markets including Saudi Arabia. We plan to commence enrollment this summer in our confirmatory study of Multikine in head and neck cancer. Data from this study will be submitted as part of registration applications to allow commercialization and sale of Multikine in the U.S. and other key global markets. Prior studies have shown that pre-surgical tumor responses, such as tumor size reduction and downgrading of the disease by a physician, following Multikine treatment predict substantial survival benefit for the patients. We believe that these pre-surgical tumor responses after the three-week treatment with Multikine, before any other treatment has been administered, could be the basis of an accelerated marketing application for Multikine,” stated CEL-SCI CEO, Geert Kersten. “Concurrently, we have been active in Saudi Arabia, pursuing the potential for Multikine to be available to patients with head and neck cancer following the filing for Breakthrough Medicine Designation there in the second half of 2025.”
https://www.stocktitan.net/news/CVM/cel-sci-r...dwmth.html
